Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1442608 | 0.85 | RAB9A (0.70) | RAB9AKMT2ASMN1; SMN2TSHRNPC1 | |
| SCHEMBL3275319 | 0.83 | RAB9A (0.68) | RAB9AKMT2ASMN1; SMN2TSHRNPC1 | |
| SCHEMBL13058919 | 0.81 | RAB9A (0.59) | RAB9AKMT2ASMN1; SMN2TSHRNPC1 | |
| SCHEMBL30182732 | 0.81 | RAB9A (0.55) | RAB9AKMT2ASMN1; SMN2TSHRNPC1 | |
| SCHEMBL30182835 | 0.79 | RAB9A (0.69) | RAB9AKMT2ASMN1; SMN2TSHRNPC1 | |
| SCHEMBL31324117 | 0.79 | DPP4 (0.60) | RAB9ASMN1; SMN2NPC1GAA | |
| SCHEMBL13058939 | 0.78 | RAB9A (0.67) | RAB9AKMT2ASMN1; SMN2TSHRNPC1 | |
| SCHEMBL3861151 | 0.77 | KMT2A (0.61) | RAB9AKMT2ASMN1; SMN2MEN1ATM | |
| SCHEMBL20924642 | 0.75 | KMT2A (0.65) | RAB9AKMT2ASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL20924603 | 0.75 | SMN1; SMN2 (0.60) | RAB9AKMT2ASMN1; SMN2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20230085372-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | C5, CFH, C1QBP | RAB9A 1696/4885KMT2A 4482/4885SMN1; SMN2 659/4885 |
| US-20230085372-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, CFH, C1QBP | RAB9A 1696/4885KMT2A 4482/4885SMN1; SMN2 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.